<p>美国信托在最近向证券交易委员会提交的文件中表示，在第二季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的股份增加了 36.8%。该基金在此期间购买了 6,421 股后，持有该公司 23,890 股股票。美国信托在艾伯维的持股在最近一个季度末价值为 4,434,000 美元。</p>
<ul>
<li>分红强者：3 只为长期投资而生的蓝筹股</li>
</ul>
<p>其他一些机构投资者也买卖了 ABBV 的股票。Marshall &amp; Sullivan Inc. WA 在第二季度购买了价值约 25,000 美元的艾伯维新股份。Evolution Wealth Management Inc.在第二季度购买了价值 26,000 美元的艾伯维新股份。TD Capital Management LLC 在第一季度将其在艾伯维的股份增加了 82.9%。TD Capital Management LLC 现在持有 128 股该公司股票，价值 27,000 美元，此前在上个季度又购买了 58 股。Spurstone Advisory Services LLC 在第二季度购买了价值 28,000 美元的艾伯维新股份。最后，Financial Gravity Companies Inc.在第二季度购买了价值约 36,000 美元的艾伯维新股份。机构投资者持有该公司 70.23% 的股票。</p>
<h2>分析师评级变动</h2>
<p>ABBV 成为多份分析师报告的主题。Guggenheim 在 10 月 20 日的研究报告中将艾伯维的目标价从 227.00 美元上调至 242.00 美元，并给予该股票 “买入” 评级。Wall Street Zen 在周六的研究报告中将艾伯维的评级从 “买入” 上调至 “强力买入”。Cantor Fitzgerald 在 10 月 9 日的报告中为艾伯维设定了 250.00 美元的目标价，并给予公司 “增持” 评级。BMO Capital Markets 在 9 月 12 日的报告中将艾伯维的目标价从 215.00 美元上调至 240.00 美元，并给予该股票 “跑赢大盘” 评级。最后，花旗集团在 11 月 3 日的研究报告中将艾伯维的目标价从 240.00 美元下调至 235.00 美元，并为公司设定了 “中性” 评级。三位分析师给予该股票 “强力买入” 评级，十四位分析师给予 “买入” 评级，八位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 244.55 美元。</p>
<ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
<p><strong>查看我们关于艾伯维的最新报告</strong></p>
<h2>艾伯维股价下跌 0.2%</h2>
<p>ABBV 的股票在周一开盘价为 223.45 美元。该公司的速动比率为 0.60，流动比率为 0.72，债务与股本比率为 44.14。该公司的 50 日移动平均线为 227.25 美元，200 日移动平均线为 209.95 美元。艾伯维公司 52 周最低价为 164.39 美元，52 周最高价为 244.81 美元。该股票的市值为 3949.2 亿美元，市盈率为 169.28，市盈增长比率为 1.21，贝塔值为 0.36。</p>
<ul>
<li>医疗保健轮换正在进行：3 只领先股票</li>
</ul>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 10 月 31 日发布了季度收益数据。该公司报告本季度每股收益为 1.86 美元，超出市场共识预期的 1.77 美元，超出 0.09 美元。该公司本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。艾伯维的净利润率为 4.00%，股本回报率为 3,216.47%。与去年同期相比，该公司的季度收入增长了 9.1%。在去年同期，该公司每股收益为 3.00 美元。艾伯维已将其 2025 年第四季度的指引设定为 3.320-3.360 每股收益。研究分析师预测艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
<h2>艾伯维增加分红</h2>
<p>该公司最近宣布了一项季度分红，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得 1.73 美元的分红。除息日期为 1 月 16 日（星期五）。这代表着年化分红为 6.92 美元，分红收益率为 3.1%。这比艾伯维之前的季度分红 1.64 美元有所增加。艾伯维的派息比率为 496.97%。</p>
<h2>艾伯维公司简介</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性疾病和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比艾伯维更好</li>
<li>NYSE 股票为投资者提供多种优质选择</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了实施阶段</li>
<li>分红贵族名单中的最佳：通过贵族指数积累财富</li>
<li>10 年期国债利率上升时值得购买的 3 只金融股票</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>美国信托在第二季度将其在艾伯维（AbbVie Inc.）的持股增加了 36.8%，目前持有价值 443 万美元的股份。其他几家机构投资者也购买了该公司的股票。分析师对艾伯维的共识评级为 “适度买入”，平均目标价为 244.55 美元。艾伯维报告第三季度每股收益为 1.86 美元，超出预期，并将季度股息提高至 1.73 美元。该公司的市值为 3949.2 亿美元，市盈率为 169.28</p>

<p>American Trust raised its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 36.8% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 23,890 shares of the company's stock after purchasing an additional 6,421 shares during the period. American Trust's holdings in AbbVie were worth $4,434,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>美国信托在最近向证券交易委员会提交的文件中表示，在第二季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的股份增加了 36.8%。该基金在此期间购买了 6,421 股后，持有该公司 23,890 股股票。美国信托在艾伯维的持股在最近一个季度末价值为 4,434,000 美元。</p>
</div><ul>
<li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li>
</ul>
<div class="lb-trans"><ul>
<li>分红强者：3 只为长期投资而生的蓝筹股</li>
</ul>
</div><p>A number of other institutional investors have also bought and sold shares of ABBV. Marshall &amp; Sullivan Inc. WA bought a new stake in shares of AbbVie during the second quarter valued at about $25,000. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the 2nd quarter valued at $26,000. TD Capital Management LLC lifted its stake in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after acquiring an additional 58 shares during the last quarter. Spurstone Advisory Services LLC purchased a new stake in AbbVie in the second quarter worth $28,000. Finally, Financial Gravity Companies Inc. purchased a new stake in AbbVie in the second quarter worth about $36,000. Institutional investors own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者也买卖了 ABBV 的股票。Marshall &amp; Sullivan Inc. WA 在第二季度购买了价值约 25,000 美元的艾伯维新股份。Evolution Wealth Management Inc.在第二季度购买了价值 26,000 美元的艾伯维新股份。TD Capital Management LLC 在第一季度将其在艾伯维的股份增加了 82.9%。TD Capital Management LLC 现在持有 128 股该公司股票，价值 27,000 美元，此前在上个季度又购买了 58 股。Spurstone Advisory Services LLC 在第二季度购买了价值 28,000 美元的艾伯维新股份。最后，Financial Gravity Companies Inc.在第二季度购买了价值约 36,000 美元的艾伯维新股份。机构投资者持有该公司 70.23% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>ABBV has been the topic of a number of analyst reports. Guggenheim upped their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, October 20th. Wall Street Zen upgraded AbbVie from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the company an &#34;overweight&#34; rating in a report on Thursday, October 9th. BMO Capital Markets raised their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, September 12th. Finally, Citigroup lowered their price objective on shares of AbbVie from $240.00 to $235.00 and set a &#34;neutral&#34; rating for the company in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $244.55.</p>
<div class="lb-trans"><p>ABBV 成为多份分析师报告的主题。Guggenheim 在 10 月 20 日的研究报告中将艾伯维的目标价从 227.00 美元上调至 242.00 美元，并给予该股票 “买入” 评级。Wall Street Zen 在周六的研究报告中将艾伯维的评级从 “买入” 上调至 “强力买入”。Cantor Fitzgerald 在 10 月 9 日的报告中为艾伯维设定了 250.00 美元的目标价，并给予公司 “增持” 评级。BMO Capital Markets 在 9 月 12 日的报告中将艾伯维的目标价从 215.00 美元上调至 240.00 美元，并给予该股票 “跑赢大盘” 评级。最后，花旗集团在 11 月 3 日的研究报告中将艾伯维的目标价从 240.00 美元下调至 235.00 美元，并为公司设定了 “中性” 评级。三位分析师给予该股票 “强力买入” 评级，十四位分析师给予 “买入” 评级，八位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 244.55 美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
</div><p><strong>View Our Latest Report on AbbVie</strong></p>
<div class="lb-trans"><p><strong>查看我们关于艾伯维的最新报告</strong></p>
</div><h2>AbbVie Trading Down 0.2%</h2>
<div class="lb-trans"><h2>艾伯维股价下跌 0.2%</h2>
</div><p>Shares of ABBV opened at $223.45 on Monday. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The firm's fifty day moving average is $227.25 and its two-hundred day moving average is $209.95. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock has a market cap of $394.92 billion, a PE ratio of 169.28, a price-to-earnings-growth ratio of 1.21 and a beta of 0.36.</p>
<div class="lb-trans"><p>ABBV 的股票在周一开盘价为 223.45 美元。该公司的速动比率为 0.60，流动比率为 0.72，债务与股本比率为 44.14。该公司的 50 日移动平均线为 227.25 美元，200 日移动平均线为 209.95 美元。艾伯维公司 52 周最低价为 164.39 美元，52 周最高价为 244.81 美元。该股票的市值为 3949.2 亿美元，市盈率为 169.28，市盈增长比率为 1.21，贝塔值为 0.36。</p>
</div><ul>
<li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗保健轮换正在进行：3 只领先股票</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 10 月 31 日发布了季度收益数据。该公司报告本季度每股收益为 1.86 美元，超出市场共识预期的 1.77 美元，超出 0.09 美元。该公司本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。艾伯维的净利润率为 4.00%，股本回报率为 3,216.47%。与去年同期相比，该公司的季度收入增长了 9.1%。在去年同期，该公司每股收益为 3.00 美元。艾伯维已将其 2025 年第四季度的指引设定为 3.320-3.360 每股收益。研究分析师预测艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
</div><h2>AbbVie Increases Dividend</h2>
<div class="lb-trans"><h2>艾伯维增加分红</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is a boost from AbbVie's previous quarterly dividend of $1.64. AbbVie's payout ratio is 496.97%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度分红，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得 1.73 美元的分红。除息日期为 1 月 16 日（星期五）。这代表着年化分红为 6.92 美元，分红收益率为 3.1%。这比艾伯维之前的季度分红 1.64 美元有所增加。艾伯维的派息比率为 496.97%。</p>
</div><h2>AbbVie Company Profile</h2>
<div class="lb-trans"><h2>艾伯维公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性疾病和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比艾伯维更好</li>
<li>NYSE 股票为投资者提供多种优质选择</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了实施阶段</li>
<li>分红贵族名单中的最佳：通过贵族指数积累财富</li>
<li>10 年期国债利率上升时值得购买的 3 只金融股票</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

美国信托公司持有艾伯维公司价值 443 万美元的股票